Predictive Oncology
Pittsburgh, US · Delaware corporation · 1 known investors
Predictive Oncology combines machine learning with data from a large privately held biobank of over 150,000 tumor samples and 3D in vitro tumor models to predict drug response for pre-clinical drug discovery. It also offers tumor drug-response testing and genomic profiling services to personalize cancer therapies, serving biopharma partners and clinical oncology.
Founders & leadership
JB
Josh BlacherinExecutive
RV
Raymond VennareinExecutive
CI
Carl I SchwartzExecutive
BM
Bob MyersinExecutive
JK
Joshua KornbergExecutive
DJ
David JohnsonExecutive
Board
RK
Ricardo KoenigsbergerBoard director
VR
Veena RaoBoard director
CN
Chuck NuzumBoard director
MH
Matthew HawrylukBoard director
GS
Gregory S. St. Clair, Sr.Board director
DH
Dan HadleyBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$275.9M disclosed across 15 rounds · 2014–2025
▶$50.8MraisedOct 2025 · 29 investors · OtherRule 506(b)
▶$50.8MraisedOct 2025 · 29 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Matthew HawrylukDirector
- Chuck NuzumDirector
- Josh BlacherExecutive Officer
- Shawn MatthewsDirector
- Veena RaoDirector
- Gregory S. St. Clair, Sr.Director
- Raymond F. VennareExecutive Officer, Director
- Thomas L. McLaughlinExecutive Officer
- Dan HadleyDirector
- Offering amount
- $50.8M
- Amount sold
- $50.8M
- Sales commissions
- $2.5M
- Placement agents
- H. C. Wainwright & Co., LLC
- First sale
- Oct 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$173.3MraisedOct 2025 · 20 investors · OtherRule 506(b)
▶$173.3MraisedOct 2025 · 20 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Chuck NuzumDirector
- Veena RaoDirector
- Dan HadleyDirector
- Gregory S. St. Clair, Sr.Director
- Matthew HawrylukDirector
- Raymond F. VennareExecutive Officer, Director
- Josh BlacherExecutive Officer
- Thomas L. McLaughlinExecutive Officer
- Shawn MatthewsDirector
- Offering amount
- $173.3M
- Amount sold
- $173.3M
- First sale
- Oct 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$413.1KraisedSep 2025 · 1 investors · BiotechnologyRule 506(b)
▶$413.1KraisedSep 2025 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nancy Chung-WelchDirector
- Dan HadleyDirector
- Raymond F. BennareExecutive Officer, Director
- Chuck NuzumDirector
- Josh BlacherExecutive Officer
- Veena RaoDirector
- Matthew HawrylukDirector
- Gregory S. St. Clair, Sr.Director
- Offering amount
- $413.1K
- Amount sold
- $413.1K
- First sale
- Aug 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.2MraisedAug 2024 · 8 investors · BiotechnologyRule 506(b)
▶$2.2MraisedAug 2024 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Veena RaoDirector
- Chuck NuzumDirector
- Matthew HawrylukDirector
- Josh BlacherExecutive Officer
- Gregory S. St. Clair, Sr.Director
- Dan HadleyDirector
- Raymond VennareExecutive Officer, Director
- Nancy Chung-WelchDirector
- Offering amount
- $2.2M
- Amount sold
- $2.2M
- Sales commissions
- $262.8K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.3MraisedJun 2022 · 4 investors · BiotechnologyRule 506(b)
▶$2.3MraisedJun 2022 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- J Melville EngleExecutive Officer, Director
- Christina JenkinsDirector
- Nancy Chung-WelchDirector
- Daniel E HandleyDirector
- Bob MyersExecutive Officer
- Raymond VennareDirector
- Chuck NuzumDirector
- Gregory St. ClairDirector
- Offering amount
- $2.3M
- Amount sold
- $2.3M
- Sales commissions
- $195.7K
- Placement agents
- H.C. Wainwright & Co. LLC
- First sale
- May 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$17.6MraisedMar 2021 · 19 investors · BiotechnologyRule 506(b)
▶$17.6MraisedMar 2021 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Carl I SchwartzExecutive Officer, Director
- Bob MyersExecutive Officer
- J Melville EngleDirector
- Nancy Chung-WelchDirector
- Daniel E HandleyDirector
- Gregory S St. Clair Sr.Director
- Chuck NuzumDirector
- Richard L GabrielDirector
- Offering amount
- $17.6M
- Amount sold
- $17.6M
- Sales commissions
- $1.6M
- Placement agents
- H.C. Wainwright & Co. LLC
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$16.8MraisedMar 2021 · 10 investors · BiotechnologyRule 506(b)
▶$16.8MraisedMar 2021 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard L GabrielDirector
- Daniel E HandleyDirector
- Gregory S St. Clair Sr.Director
- Chuck NuzumDirector
- Nancy Chung-WelchDirector
- Carl I SchwartzExecutive Officer, Director
- Bob MyersExecutive Officer
- J Melville EngleDirector
- Offering amount
- $16.8M
- Amount sold
- $16.8M
- Sales commissions
- $951K
- Placement agents
- H.C. Wainwright & Co. LLC
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.8MraisedJul 2020 · 18 investors · BiotechnologyRule 506(b)
▶$1.8MraisedJul 2020 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Andrew P RedingDirector
- Daniel E HandleyDirector
- J Melville EngleDirector
- Richard L GabrielDirector
- Carl I SchwartzExecutive Officer, Director, Promoter
- Bob MyersExecutive Officer
- Offering amount
- $1.8M
- Amount sold
- $1.8M
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Acquisitions · 1
Early investors' stakes continue via these dealszPREDICTA
zPREDICTA manufactures three-dimensional tissue culture models derived from patient samples that recreate human organ microenvironments for drug testing. Pharmaceutical companies and researchers use the models to evaluate cancer drug candidates and predict clinical efficacy before human trials.
In the news
Frequently asked questions
- What does Predictive Oncology do?
- Predictive Oncology combines machine learning with data from a large privately held biobank of over 150,000 tumor samples and 3D in vitro tumor models to predict drug response for pre-clinical drug discovery. It also offers tumor drug-response testing and genomic profiling services to personalize cancer therapies, serving biopharma partners and clinical oncology.
- Who are Predictive Oncology's investors?
- Predictive Oncology's investors include Yorkville Advisors.
- How much funding has Predictive Oncology raised?
- Predictive Oncology has disclosed $275.9M raised across 15 rounds.
- Where is Predictive Oncology headquartered?
- Predictive Oncology is headquartered in Pittsburgh, US.